Date: 2013-07-02
Type of information: R&D agreement
Compound: therapeutic antibodies from BioInvent\'s n-CoDeR® library
Company: BioInvent (Sweden) Mitsubishi Tanabe Pharma Corporation (Japan)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On July 2, 2013, BioInvent International has announced that it has signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corporation for the development of antibodies from BioInvent\'s n-CoDeR® library. Under the terms of the extension, Mitsubishi Tanabe will continue to have access to BioInvent\'s discovery and development technology platform for a further two years and can develop up to eight antibody programmes.
The n-CoDeR® library contains more than 20 billion (2 x 1010) highly diverse, fully human antibody fragments that have been created using BioInvent\'s patented approach, generating antibodies with high affinity and selectivity.
Financial terms: BioInvent will receive an undisclosed initial fee plus annual maintenance fees and success-based milestone payments as well as royalties on commercialized products.
Latest news:
